SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Care-plan review) — Pablo Neruda

PatientPablo Neruda
Date of birth1959-07-12
IdentifiersMRN HR-ML051-SYN; SSN (made up) 000-51-2976
Document date2026-09-14
AuthorMarisol Fairweather-Diaz, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month review on androgen deprivation with apalutamide, after radiotherapy to the prostate. [S]

History of Present Illness

Mr. Neruda returns three months after starting treatment, with a professional Spanish interpreter. He finished 20 fractions of radiotherapy to the prostate three weeks ago. During the last two weeks of treatment he had more frequent urination and looser stools, and both are settling: he now gets up once a night, and his bowels are once or twice a day, with no bleeding. The rash he had five weeks ago faded within two weeks on the cream and cetirizine, and he has stopped both. The hip pain has gone; he has not taken acetaminophen for three weeks. Hot flashes come four or five times a day. His weight is up 2 kg, and he tires in the afternoons but still walks daily and writes every morning. He has had no falls. His home blood pressure readings have been around 130/80 since the amlodipine increase. He asks whether the treatment is working. [S]

ElementDetail
Radiotherapy55 Gy in 20 fractions, finished three weeks ago
Urinary and bowelNocturia once; stools once or twice a day, settling; no bleeding
RashResolved; triamcinolone and cetirizine stopped
PainNone; acetaminophen stopped three weeks ago

Review of Systems

SystemResultFinding
ConstitutionalPositiveAfternoon fatigue; weight up 2 kg
EndocrinePositiveHot flashes four or five times a day; no cold intolerance or constipation
GenitourinaryPositiveNocturia once; no burning or blood
GastrointestinalPositiveSofter stools once or twice a day, settling; no bleeding
IntegumentaryNegativeRash gone
MusculoskeletalNegativeNo bone pain

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet dailyOral route2021-04-06 to 2026-07-13completedS
Amlodipine 10 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-07-13activeS
Acetaminophen 500 mg oral tablet, two tablets (1000 mg) up to three times daily as needed for bone painTwo tablets up to three times daily as neededOral route2026-06-01 to 2026-09-14completedS
Apalutamide 240 mg oral tablet, one tablet once daily, swallowed whole, with or without foodOne tablet once dailyOral route2026-06-15activeS
Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, every twelve weeksOne injection every twelve weeksIntramuscular route2026-06-22activeS
Cholecalciferol (vitamin D3) 2000 units (0.05 mg) oral tablet, one tablet dailyOne tablet dailyOral route2026-06-15activeS
Denosumab 60 mg/mL prefilled syringe, 60 mg subcutaneously every six months, for high fracture risk on androgen deprivationOne injection every six monthsSubcutaneous route2026-07-13activeS
Triamcinolone acetonide 0.1% cream, apply a thin layer to the rash twice daily for two weeks (not the face or groin)Twice daily for two weeksTopical route2026-08-10 to 2026-08-24completedS
Cetirizine 10 mg oral tablet, one tablet daily for itchOne tablet dailyOral route2026-08-10 to 2026-08-31completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-09-14Body height178cmS
2026-09-14Body weight94.2kgS
2026-09-14Body mass index (BMI) [Ratio]29.7kg/m2S
2026-09-14Systolic blood pressure132mm[Hg]S
2026-09-14Diastolic blood pressure80mm[Hg]S
2026-09-14Heart rate72/minS
2026-09-14Respiratory rate14/minS
2026-09-14Body temperature36.6CelS
2026-09-14Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-09-14Prostate specific Ag [Mass/volume] in Serum or Plasma0.18ng/mL<=4 ng/mLNormalS
2026-09-14Testosterone [Mass/volume] in Serum or Plasma14ng/dL264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivationLowS
2026-09-14Hemoglobin [Mass/volume] in Blood12.9g/dL13.2-16.6 g/dLLowS
2026-09-14Leukocytes [#/volume] in Blood by Automated count5.910*3/uL4-11 10*3/uLNormalS
2026-09-14Platelets [#/volume] in Blood by Automated count23110*3/uL150-400 10*3/uLNormalS
2026-09-14Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-09-14Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
2026-09-14Glucose [Mass/volume] in Serum or Plasma102mg/dL70-99 mg/dLHighS
2026-09-14Creatinine [Mass/volume] in Serum or Plasma0.99mg/dL0.74-1.35 mg/dLNormalS
2026-09-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M83mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-09-14Calcium [Mass/volume] in Serum or Plasma9.2mg/dL8.6-10.3 mg/dLNormalS
2026-09-14Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-55 U/LNormalS
2026-09-14Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L8-48 U/LNormalS
2026-09-14Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma96U/L40-129 U/LNormalS
2026-09-14Albumin [Mass/volume] in Serum or Plasma4g/dL3.5-5 g/dLNormalS
2026-09-14Thyrotropin [Units/volume] in Serum or Plasma5.4m[IU]/L0.45-4.5 mIU/LHighS
2026-09-14Thyroxine (T4) free [Mass/volume] in Serum or Plasma1ng/dL0.8-1.8 ng/dLNormalS
2026-09-14Hemoglobin A1c/Hemoglobin.total in Blood6.1%<=5.6%HighS
2026-09-14Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2026-09-14International Prostate Symptom Score [IPSS]9{score}S
2026-09-14Pain severity - 0-10 verbal numeric rating [Score] - Reported1{score}S

Physical Exam

Vital signs recorded on 2026-09-14; see the Vital Signs section. [S]

SystemFinding
GeneralWell
CardiovascularRegular rhythm; blood pressure 132/80 mm Hg; no ankle swelling
NeckThyroid not enlarged
SkinNo rash; mild darkening of the skin over the radiotherapy field
NeurologicalStrength and sensation normal in both legs

Problems

ProblemClinical statusVerificationCodeProvenance
Urinary frequency, weak stream and nocturia for four months, with right hip and low back pain for six weeks, a hard nodular prostate and a raised PSA; suspected prostate cancer, to be confirmedresolvedconfirmed R97.20S — Synthetic presenting problem, resolved at the second visit when biopsy and staging established metastatic prostate cancer.
Adenocarcinoma of the prostate, Grade Group 4 (Gleason 4+4), cT3a N1 M1b, de novo metastatic hormone-sensitive disease, low volume by conventional imaging (two bone metastases, in the right ilium and L5, and two pelvic lymph nodes; no visceral disease); synthetic modern detail linked to his documented prostate cancer of 1971activeconfirmed C61S — Synthetic grade, stage, extent and PSA; the prostate cancer and the operation in France in 1971 are documented (D), and no stage, grade or treatment detail was found in the sources read.
Bone metastases from prostate cancer: right iliac wing (painful) and L5 vertebral body; no cord compressionactiveconfirmed C79.51S — Synthetic metastatic sites.
Pelvic lymph node metastases: right external iliac and right obturator nodesactiveconfirmed C77.5S — Synthetic nodal disease.
Hormone-sensitive prostate canceractiveconfirmed Z19.1S — Synthetic status in the modern episode.
Continuous androgen deprivation (leuprolide) with apalutamide, with monitoring of testosterone, PSA, thyroid function, blood pressure, glucose and lipids, bone health, rash, falls, hot flashes, sexual health, mood and cognitionactiveconfirmed Z79.899S — Synthetic treatment plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy.
Essential hypertension for five years, on amlodipineactiveconfirmed I10S — Synthetic comorbidity, relevant to cardiovascular risk on androgen deprivation; not a claim about his real blood pressure.
Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL)activeconfirmed E55.9S — Synthetic finding at intake, addressed at the second visit.
Low bone mass (femoral neck T-score -2.1, L1 to L4 -1.4) with a ten-year hip fracture risk above 3% (FRAX, with androgen deprivation counted as a cause of secondary osteoporosis)activeconfirmed M85.89S — Synthetic bone-health finding on the DXA before androgen deprivation.
Prediabetes (hemoglobin A1c 5.9%)activeconfirmed R73.03S — Synthetic metabolic finding at intake, relevant to androgen deprivation.
Maculopapular drug rash from apalutamide, grade 2 (about 20 percent of body surface, trunk and upper arms), eight weeks into treatment; no mucosal involvement, blistering, fever, eosinophilia or liver involvement; settled on topical steroid and an antihistamine without stopping apalutamideresolvedconfirmed L27.0S — Synthetic intercurrent problem at an unscheduled visit; a known effect of apalutamide, not a historical claim.
Personal history of radiotherapy to the prostate (55 Gy in 20 fractions, finished three weeks before the three-month visit)activeconfirmed Z92.3S — Synthetic: recorded after the course of radiotherapy finished.
Raised TSH (5.4 mIU/L) with a normal free T4 on apalutamide: subclinical, under observationactiveconfirmed R94.6S — Synthetic finding; raised TSH is a known effect of apalutamide.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryPSA on androgen deprivationEvery 3 to 6 monthsCompleted today0.18 ng/mL at three months
LaboratoryTestosteroneEvery 3 to 6 months on androgen deprivation (target below 50 ng/dL)Completed today14 ng/dL, castrate
LaboratoryBlood countPeriodically in metastatic diseaseCompleted todayHemoglobin 12.9 g/dL (mildly low); white cells and platelets normal
LaboratoryChemistry with calcium and alkaline phosphatasePeriodically on denosumab and in metastatic diseaseCompleted todayCalcium 9.2 mg/dL; creatinine 0.99 mg/dL; alkaline phosphatase 96 U/L, normal
LaboratoryTSH and free T4 on apalutamideAbout every four monthsCompleted todayTSH 5.4 mIU/L (raised); free T4 1.0 ng/dL (normal)
LaboratoryHemoglobin A1cBaseline and yearly on androgen deprivation; repeated at three months for prediabetesCompleted today6.1 percent, up from 5.9
LaboratoryLipid panelBaseline and yearly on androgen deprivationUp to dateBaseline at the first visit; statin decision at the annual wellness visit
ImagingBone density (DXA)Every 1 to 2 years on androgen deprivationUp to dateBaseline three months ago
ImagingRestaging imagingIf PSA rises or symptoms appearNot indicatedPSA 0.18 ng/mL and no symptoms
ExaminationBlood pressure and cardiovascular assessmentEvery visit on androgen deprivationCompleted today132/80 mm Hg on amlodipine 10 mg; home readings about 130/80
ExaminationNeurological check for spinal cord compressionEvery visit with spinal metastasesCompleted todayNormal
SurveyDistress and depression screen (PHQ-2)At intervalsCompleted todayPHQ-2 score 1
SurveyPain scoreEvery visit with symptomatic metastasesCompleted today1 of 10
SurveyUrinary symptoms (IPSS)Every follow-up visit, particularly after radiotherapyCompleted todayIPSS 9, down from 17
SurveyBowel function after radiotherapyEvery visit after radiotherapyCompleted todaySofter stools once or twice a day, settling; no bleeding
SurveySexual functionPeriodically on androgen deprivationCompleted todayLower libido and erections, as expected; no treatment wanted now
SurveyCognitionPeriodically on androgen deprivationDueMini-Cog at the annual wellness visit in three weeks
Medication safetyRash on apalutamideEvery visit on androgen deprivationCompleted todayResolved
Medication safetyFalls on apalutamideEvery visit on androgen deprivationCompleted todayNo falls
Medication safetyHot flashes and fatigueEvery visit on androgen deprivationCompleted todayHot flashes four or five times a day; afternoon fatigue; no medicine wanted yet
Medication safetySecond leuprolide injectionEvery twelve weeksCompleted todayGiven today
ReferralSomatic tumor testing resultOnceCompleted todayNo homologous recombination repair alteration; microsatellite stable
Self-managementPhysical activity, weight and calcium intakeEvery visitCompleted todayWalking daily; resistance exercise twice a week; calcium from food

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026 (2026); ERLEADA (apalutamide) tablets: prescribing information (2026); CMID: Clinical Monitoring Intelligence Database, prostate cancer and hypertension monographs (2026)

Follow-up: Annual wellness visit in three weeks. TSH and free T4 in about eight weeks. Medical oncology and the third leuprolide injection in twelve weeks, with PSA and testosterone. Denosumab again in four months. Next scheduled visit 2026-10-05: subsequent annual wellness visit. [S]